Development of a type II diabetic mellitus animal model using Micropig(R).
10.5625/lar.2012.28.3.205
- Author:
Myeong Seop LEE
1
;
Ki Duk SONG
;
Hee Jun YANG
;
Chester D SOLIS
;
Soo Hyeon KIM
;
Woon Kyu LEE
Author Information
1. Medikinetics Co., Ltd., Pyeong-Taek, Korea.
- Publication Type:Letter
- Keywords:
Type 2 diabetic mellitus;
Micropig;
glucose level;
NIA;
STZ
- MeSH:
Animals;
Blood Glucose;
Gastrointestinal Tract;
Glucose;
Glucose Tolerance Test;
Humans;
Immunohistochemistry;
Incidence;
Insulin;
Male;
Models, Animal;
Niacinamide;
Pancreas;
Swine
- From:Laboratory Animal Research
2012;28(3):205-208
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diabetes, which has shown an explosive increase in terms of its incidence, is regarded as a serious disease that must be overcome for the sake of human life. Among animal models used for testing of drug efficacy, the mini-pig model has shown a rapid upload due to its many similarities with human, particularly concerning the pharmacokinetics of compounds after subcutaneous administration, the structure and function of the gastrointestinal tract, the morphology of the pancreas, and overall metabolic status. Based on these various advantages, we sought to develop an animal model of type II diabetic mellitus using the Micro-pig, which differs from other miniature pigs. We used six male Micro-pigs for induction of a moderate insulin deficient model with nicotinamide (NIA)/streptozotocin (STZ) treatment and three animals for control. For evaluation of incidence of type II diabetes, we measured blood glucose level, and performed oral glucose tolerance test and immunohistochemistry on pancreatic tissue using insulin antibody. Compared to control animals, all animals treated with NIA/STZ showed high levels of glucose and low levels of insulin. In addition, we observed the partially destroyed beta cell population from tissue of the pancreas in treated animals. Based on these results, we report that the Micro-pig model developed in this study can be used for testing of the efficacy of therapeutic agents for treatment of Type 2 diabetic mellitus.
